Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Y
338840
vs
K
KOSPI 200
Over the past 12 months, Y Biologics Inc has underperformed KOSPI 200, delivering a return of -46% compared to KOSPI 200's +116% growth.
Stocks Performance
338840 vs KOSPI 200
Performance Gap
338840 vs KOSPI 200
Performance By Year
338840 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Y Biologics Inc
Glance View
Y Biologics is a South Korean biotechnology company that discovers and develops therapeutic antibodies. It builds antibody drug candidates for diseases such as cancer and immune disorders, using its own antibody discovery platform and internal research programs. Rather than selling consumer products, it works at the early stage of drug development, where the main job is finding strong antibody leads and turning them into medicines that can be tested in clinical trials. Its customers are mainly pharmaceutical and biotech companies that want access to new antibody candidates or discovery technology, along with research partners involved in joint development. Y Biologics makes money through collaboration research fees, licensing deals, milestone payments, and potential royalties if partnered drugs reach the market. It may also earn value from advancing its own pipeline and then partnering it out to larger drugmakers. What makes its business different is its role in the drug value chain: it is a source of antibody technology and early assets, not a large-scale manufacturer or drugstore-style seller. That means its success depends on scientific results, patent protection, and the ability to sign partnering deals with companies that have the resources to run expensive late-stage development and commercialization.